Ftse Mib
33.364,79
-0,39%
DAX
19.379,25
0,38%
S&P 500
5.969,34
0,35%
NASDAQ
19.003,65
0,00%
Bitcoin
97.863,67
-0,18%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Apollomics Inc (APLMW) Apollomics Inc (APLMW) Notizie

APLMW

Apollomics (APLMW)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:APLMW
DataOraFonteTitoloSimboloCompagnia
14/11/202423:25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:APLMWApollomics Inc
13/08/202416:50AllPennyStocks.comBiotech Sees Massive Buying Pressure Following Phase 2 Preliminary DataNASDAQ:APLMWApollomics Inc
04/06/202414:00GlobeNewswire Inc.Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:APLMWApollomics Inc
30/05/202422:15Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:APLMWApollomics Inc
30/05/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:APLMWApollomics Inc
29/05/202423:12Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:APLMWApollomics Inc
29/05/202414:00GlobeNewswire Inc.Apollomics Announces Presentation at the 2024 BIO International ConventionNASDAQ:APLMWApollomics Inc
24/05/202422:58Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:APLMWApollomics Inc
20/05/202422:32Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:APLMWApollomics Inc
20/05/202422:15Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:APLMWApollomics Inc
08/05/202422:05GlobeNewswire Inc.Apollomics Announces Private Placement Financing and Addition to Board of DirectorsNASDAQ:APLMWApollomics Inc
25/04/202414:30GlobeNewswire Inc.Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion GeneNASDAQ:APLMWApollomics Inc
10/04/202413:00GlobeNewswire Inc.Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:APLMWApollomics Inc
02/04/202414:00GlobeNewswire Inc.Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:APLMWApollomics Inc
28/03/202412:00GlobeNewswire Inc.Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial ResultsNASDAQ:APLMWApollomics Inc
26/03/202413:00GlobeNewswire Inc.Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024NASDAQ:APLMWApollomics Inc
04/03/202413:00GlobeNewswire Inc.Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial OfficerNASDAQ:APLMWApollomics Inc
07/02/202413:00GlobeNewswire Inc.Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:APLMWApollomics Inc
19/01/202422:15GlobeNewswire Inc.Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:APLMWApollomics Inc
17/01/202422:30GlobeNewswire Inc.Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology ConferenceNASDAQ:APLMWApollomics Inc
03/01/202413:00GlobeNewswire Inc.Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid LeukemiaNASDAQ:APLMWApollomics Inc
02/01/202422:30GlobeNewswire Inc.Apollomics to Present at the 2024 Biotech ShowcaseNASDAQ:APLMWApollomics Inc
04/12/202313:00GlobeNewswire Inc.Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping MutationNASDAQ:APLMWApollomics Inc
29/11/202313:30GlobeNewswire Inc.Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceNASDAQ:APLMWApollomics Inc
28/11/202313:00GlobeNewswire Inc.Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)NASDAQ:APLMWApollomics Inc
16/11/202314:30GlobeNewswire Inc.Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung CancerNASDAQ:APLMWApollomics Inc
31/10/202313:30GlobeNewswire Inc.Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET DysregulationNASDAQ:APLMWApollomics Inc
26/10/202314:50GlobeNewswire Inc.Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET FusionNASDAQ:APLMWApollomics Inc
23/10/202314:30GlobeNewswire Inc.Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%NASDAQ:APLMWApollomics Inc
17/10/202300:55GlobeNewswire Inc.Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023NASDAQ:APLMWApollomics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:APLMW

La tua Cronologia

LSE
47FK
Int.fin.46
NASDAQ
ABKOXXX
Ubs Ag London Branch Iss...
DBI
I1R9
Xtr Bloomberg Commodity ...
TSXV
NZP
Chatham Rock Phosphate
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network